Impact Analysis of COVID-19 on Global Leukemia Therapeutics Market Outlook 2028

  • Product Code:
    RP-ID-10336410
  • Published Date:
    6 Oct 2020
  • Region:
    Global
  • Pages:
    200
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Pub-ID-9

Impact Analysis on the Growth of Market

Activating Probable Propositions Amidst COVID-19 Crisis

With things going haywire, we analyze key points to make sure that the businesses around the globe are completely prepared to tackle potential implications caused by COVID-19. Be it protecting employees, customers or the overall business operations, we ensure that the employers take the right decisions, make strategic investments and maintain a healthy work culture along with taking probable measures to minimize the financial loss. Know More

Global Leukemia Therapeutics Market Analysis – 2019-2028

Leukemia therapeutics are effective drugs & biologics capable of generating a therapeutic effect on a leukemia patient by slowing down the growth or killing the cancer cells. The global leukemia therapeutics market is anticipated to achieve a CAGR of 10.81% across the globe over the forecast period, 2021-2028. Factors such as the continuous advancements and development for blood cancer testing, increasing number of patients with leukemia, which is raising the need for advanced treatment solutions, increasing R & D investments and the growing advancements in technology in the healthcare sector are anticipated to promote towards the growth of the global leukemia therapeutics market. Additionally, factors such as the growing concern for leukemia, which is also raising the need for the effective treatment of the disease, is anticipated to drive the growth of the global leukemia therapeutics market.
The global leukemia therapeutics market consists of various segments that are segmented by application, drug class, route of administration, therapy, end user and by region. The market is further segmented by application into acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia and others. Out of these, the chronic lymphocytic leukemia segment is anticipated to register the largest market share by growing at a CAGR of around 10% during the forecast period. Chronic Lymphocytic Leukemia is the most common type of leukemia in adults in the world's Western part. According to the American Cancer Society, Chronic Lymphocytic Leukemia accounts for approximately one-quarter of leukemia cases. According to the National Cancer Institute, about 186,422 people were suffering from CLL in the US, in the year 2017.
Based on region, the global leukemia therapeutics market is segmented into five major regions including North America, Latin America, Europe, Asia Pacific, Middle East and Africa. The market in Europe registered a significant market share of around 29% in the year 2019 and is primarily driven by nations such as the UK, Germany, France, Italy and others. The market in Europe is further anticipated to gain an incremental $ opportunity of around USD 328.39 million in the year 2020 as compared to the previous year.
Some of the affluent industry leaders in the global leukemia therapeutics market are Amgen Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc., Novartis AG, AbbVie Inc., Sanofi and Gilead Sciences.

Global Leukemia Therapeutics Market


1. INTRODUCTION
1.1. MARKET DEFINITION
1.2. PRODUCT OVERVIEW
2. ASSUMPTIONS AND ACRONYMS
3. RESEARCH METHODOLOGY
4. EXECUTIVE SUMMARY- GLOBAL LEUKEMIA THERAPEUTICS MARKET
5. REGULATORY LANDSCAPE
6. EPIDEMIOLOGY ANALYSIS
7. MARKET DYNAMICS
7.1. GROWTH DRIVERS
7.2. KEY TRENDS
7.3. KEY MARKET OPPORTUNITIES
7.4. MAJOR ROADBLOCKS FOR THE MARKET GROWTH
8. INDUSTRY RISK ANALYSIS
8.1. DEMAND RISK ANALYSIS
8.2. SUPPLY RISK ANALYSIS
9. EVALUATION ON THE IMPACT OF COVID-19 ON THE GLOBAL LEUKEMIA THERAPEUTICS MARKET
10. GLOBAL LEUKEMIA THERAPEUTICS MARKET
10.1. MARKET SIZE (USD MILLION), 2019-2028
v SEGMENTATION BY THERAPY
· CHEMOTHERAPY, 2019-2028F (USD MILLION)
· IMMUNOTHERAPY, 2019-2028F (USD MILLION)
· TARGETED THERAPY, 2019-2028F (USD MILLION)
v SEGMENTATION BY APPLICATION
· ACUTE LYMPHOCYTIC LEUKEMIA, 2019-2028F (USD MILLION)
· CHRONIC LYMPHOCYTIC LEUKEMIA, 2019-2028F (USD MILLION)
· ACUTE MYELOID LEUKEMIA, 2019-2028F (USD MILLION)
· CHRONIC MYELOID LEUKEMIA, 2019-2028F (USD MILLION)
v SEGMENTATION BY END USER
· HOSPITALS, 2019-2028F (USD MILLION)
· CLINICS, 2019-2028F (USD MILLION)
· AMBULATORY SURGICAL CENTER, 2019-2028F (USD MILLION)
v SEGMENTATION BY REGION
· NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET OUTLOOK
§ SEGMENTATION BY COUNTRY
o U.S. & CANADA LEUKEMIA THERAPEUTICS MARKET, 2019-2028F (USD MILLION)
· EUROPE LEUKEMIA THERAPEUTICS MARKET OUTLOOK
§ SEGMENTATION BY COUNTRY
o UK, GERMANY, FRANCE, ITALY, SPAIN, RUSSIA AND REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET, 2019-2028F (USD MILLION)
· ASIA PACIFIC LEUKEMIA THERAPEUTICS MARKET OUTLOOK
§ SEGMENTATION BY COUNTRY
o CHINA, INDIA, JAPAN, SOUTH KOREA, AUSTRALIA, MALAYSIA AND REST OF ASIA PACIFIC LEUKEMIA THERAPEUTICS MARKET, 2019-2028F (USD MILLION)
· LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET OUTLOOK
§ SEGMENTATION BY COUNTRY
o BRAZIL, MEXICO & REST OF LATIN AMERICA LEUKEMIA THERAPEUTICS MARKET, 2019-2028F (USD MILLION)
· MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET OUTLOOK
§ SEGMENTATION BY COUNTRY
o GCC, ISRAEL, SOUTH AFRICA AND REST OF MIDDLE EAST & AFRICA LEUKEMIA THERAPEUTICS MARKET, 2019-2028F (USD MILLION)
11. COMPETITIVE STRUCTURE
v COMPETITIVE BENCHMARKING BY MANUFACTURER
v COMPANY PROFILES
· ROCHE
· NOVARTIS
· AMGEN
· SANOFI
· ABBVIE
· AstraZeneca
· Gilead Sciences
12. STRATEGIC RECOMMENDATIONS

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Amgen Inc., F. Hoffmann-La Roche Ltd., AstraZeneca Plc., Novartis AG, AbbVie Inc., Sanofi and Gilead Sciences

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports